Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Dental Health Advocates Want To Sink Teeth Into Health Care Reform
The Washington Post reports many oral health professionals worry that dental issues have "a tenuous place at best in the national debate" regarding an overhaul of the health care system. Still, they emphasize that dental health is an integral part of health care and note the special burden untreated dental issues have on poor children. The paper also notes that "closing the gap between the worlds of dental care and medical care, with their separate histories and cultures, and their separate finance and delivery systems would be a formidable task."
generic viagra online
British Veterinary Assoicaiton Asks DEFRA To Abandon Separation Of Animal Health From Animal Welfare
The British Veterinary Association (BVA) has called on Defra to abandon its plans for a new animal health body that will give responsibility for animal health to an independent board and leave responsibility for animal welfare with ministers. The BVA has also expressed deep concerns over the confusion caused by the new structure that could lead to delays in dealing with outbreaks of disease across the UK.
News of the day
Intimate Abuse Study Finds Clear Links With Poor Health And Calls For Holistic Primary Care Approach
Nearly a quarter of married and cohabiting women who took part in a survey said that they
Mental Health

Fingolimod And Cladribine: Two New Oral Substances Show Promising Results In Current Clinical Trials For MS Therapy

The results of current clinical trials on new substances for MS therapy are among the new research findings that are being discussed with particular interest at the ENS meeting. Professor Comi is part of an international research team presenting the latest results of a study involving the orally administered drug fingolimod that is still in the clinical trial state and yet to be approved. An earlier study showed that oral fingolimod reduced the annualizied relapse rate in MS patients by more than 50 percent versus placebo. The new data now being presented by Professor Comi and his colleagues document developments over a longer period of time. "After four years, patients continuously treated with the substance had a low relapse rate, and 63% to 70% of these patients remain relapse free," the expert reports. "The majority of those patients treated also remained free from inflammatory activity and disability progression." Another trial being presented in Milan by an international study group investigated the efficacy of a cladribine tablet therapy that is also in development. "Cladribine is a prodrug, and selective effects on lymphocytes provide targeted and sustained immunomodulation, permitting the investigation of an oral short-course annual treatment," Professor Comi explained. The CLARTY study included 1,326 patients with relapsing remitting multiple sclerosis. The results, summarized by Professor Comi, are very promising: "Treatment with two different doses cladribine tablets in the CLARTY study resulted in a significant reduction in relapse rates (-58% for low dose and -55% for high dose) and significant reduction in disability progression relative to placebo with both doses. When taken alongside the MRI and safety data, the results provide clear evidence supporting the key role of the drug in the treatment of relapsing remitting multiple sclerosis." European Neurological Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009